The U.S. Food and Drug Administration yesterday asked Endo Pharmaceuticals to remove its opioid pain medication Opana ER from the market, citing the potential for the reformulated drug to be abused. “We will continue to take regulatory steps when we see situations where an opioid product’s risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse,” said FDA Commissioner Scott Gottlieb, M.D.
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Hospitals and clinicians are seeing fewer flu patients this season than in other recent years, the Centers for Disease Control and Prevention reports.
Insights and Analysis
Share how your organization is working to improve health equity – apply for the AHA Equity of Care Award Applications for the 2019 AHA Equity of Care Award are due by Feb. 19
Please consider applying for the award and sharing how your organization is improving health equity and value.
Senate Health, Education, Labor and Pensions Committee Chairman Lamar Alexander, R-Tenn., today convened a hearing on “Managing Pain During the Opioid Crisis”…
The Centers for Medicare…
Members of the pharmaceutical distribution supply chain, including dispensers such as hospitals and pharmacies, can apply through March 11 to participate in a…